HALO
Halozyme Therapeutics Inc.

4,880
Mkt Cap
$8.43B
Volume
2.04M
52W High
$79.50
52W Low
$47.50
PE Ratio
15.07
HALO Fundamentals
Price
$71.71
Prev Close
$73.34
Open
$73.34
50D MA
$68.93
Beta
0.72
Avg. Volume
2.13M
EPS (Annual)
$3.43
P/B
16.72
Rev/Employee
$2.9M
Loading...
Loading...
News
all
press releases
AlphaQuest LLC Acquires 34,011 Shares of Halozyme Therapeutics, Inc. $HALO
AlphaQuest LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 640.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Wall Street Zen
Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday...
MarketBeat·8h ago
News Placeholder
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·1d ago
News Placeholder
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Zacks·1d ago
News Placeholder
Q4 EPS Forecast for Halozyme Therapeutics Lifted by Analyst
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research increased their Q4 2025 earnings per share estimates for shares of Halozyme Therapeutics in a report issued...
MarketBeat·1d ago
News Placeholder
Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO
Great Lakes Advisors LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.9% during the third quarter, according to its most recent 13F filing with the...
MarketBeat·1d ago
News Placeholder
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
Halozyme Therapeutics' shares jump nearly 4% after preliminary 2025 results beat expectations and management lifts 2026 outlook.
Zacks·2d ago
News Placeholder
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance
Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2026 earnings guidance. The company provided EPS guidance of 7.750-8.250 for the period, compared to the consensus estimate of 7.860. The company...
MarketBeat·2d ago
News Placeholder
Federated Hermes Inc. Has $106.40 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO
Federated Hermes Inc. raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 294.1% in the third quarter, according to the company in its most recent disclosure with the...
MarketBeat·2d ago
News Placeholder
HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition
The biopharmaceutical company said that it now expects 2025 total revenue of $1.385 - $1.4 billion, representing a year-on-year growth of up to 38%.
Stocktwits·3d ago
<
1
2
...
>

Latest HALO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.